Claims for Patent: 9,969,805

Summary for Patent: 9,969,805

Title:	Amino acid sequences directed against HER2 and polypeptides comprising the same for the treatment of cancers and/or tumors
Abstract:	The present invention relates to amino acid sequences and Nanobodies that are directed against Epidermal Growth Factor Receptor 2 (HER2), as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
Inventor(s):	Revets; Hilde Adi Pierrette (Meise, BE), Boutton; Carlo (Wielsbeke, BE), Hoogenboom; Hendricus Renerus Jacobus Mattheus (Maastricht, NL)
Assignee:	Ablynx N.V. (Ghent-Zwijnaarde, BE)
Application Number:	14/592,022
Patent Claims:	1. Biparatopic construct which comprises at least one single variable domain directed against a first epitope of HER2 and at least one single variable domain directed against a second epitope of HER2 different from the first epitope, wherein the biparatopic construct contains at least one single variable domain that binds to domain II of HER2, that binds to the pertuzumab binding site on HER2 and/or that competes with pertuzumab for binding HER2 and that essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which: CDR1 is the amino acid sequence of SEQ ID NO: 464; and CDR2 is the amino acid sequence of SEQ ID NO: 1014; and CDR3 is the amino acid sequence of SEQ ID NO: 1564. 2. Biparatopic construct according to claim 1, that contains at least one single variable domain that binds to domain IV of HER2, that binds to the trastuzumab binding site on HER2 and/or that competes with trastuzumab for binding HER2. 3. Biparatopic construct according to claim 2, wherein said at least one single variable domain that essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which: CDR1 is chosen from the group consisting of: the amino acid sequences of SEQ ID NOs: 401-463; and CDR2 is chosen from the group consisting of: the amino acid sequences of SEQ ID NOs: 951-1013; and CDR3 is chosen from the group consisting of: the amino acid sequences of SEQ ID NOs: 1501-1563; and wherein CDR1, CDR2, and CDR3 sequences are combined as mentioned on the same line in Table A-I. 4. Biparatopic construct according to claim 2, wherein the CDR sequences of said at least one single variable domain have essentially 100% amino acid identity with the CDR sequences of at least one of the single variable domains of SEQ ID NOs: 2051-2113. 5. Biparatopic construct according to claim 2, wherein said at least one single variable domain is chosen from the group consisting of SEQ ID NOs: 2051-2113. 6. Biparatopic construct according to claim 1, that contains at least one single variable domain that binds HER2 and that cross-blocks the binding to HER2 of at least one of the single variable domains chosen from the group consisting of SEQ ID NOs: 2051-2113 and/or that is cross-blocked from binding to HER2 by at least one of the single variable domains chosen from the group consisting of SEQ ID NOs: 2051-2113. 7. Biparatopic construct according to claim 1, that contains at least one single variable domain in which the CDR sequences of said at least one single variable domain have 100% amino acid identity with the CDR sequences of the single variable domain of SEQ ID NO: 2114. 8. Biparatopic construct according to claim 1, that contains at least one single variable domain that is SEQ ID NO: 2114. 9. Biparatopic construct according to claim 1, that contains at least one single variable domain in which the CDR sequences of said at least one single variable domain have essentially 100% amino acid identity with the CDR sequences of at least one of the single variable domains of SEQ ID NOs: 2051-2113 and that contains at least one single variable domain in which the CDR sequences of said at least one single variable domain have 100% amino acid identity with the CDR sequences of the single variable domain of SEQ ID NO: 2114. 10. Biparatopic construct according to claim 1, that contains at least one single variable domain that is chosen from the group consisting of SEQ ID NOs: 2051-2113 and that contains at least one single variable domain that is SEQ ID NO: 2114. 11. Biparatopic construct according to claim 1, wherein at least one of the at least one single variable domain is a domain antibody, a single domain antibody, a VHH sequence, a humanized VHH sequence, or a camelized heavy chain variable domain. 12. Biparatopic construct according to claim 1, that is chosen from the group consisting of SEQ ID NOs: 2342, 2346, 2347, and 2348. 13. Biparatopic construct according to claim 1, that further comprises one or more other groups, residues, moieties or binding units. 14. Biparatopic construct according to claim 13, in which said one or more other groups, residues, moieties or binding units provide the construct with increased half-life, compared to the corresponding construct without the one or more other groups, residues, moieties or binding units. 15. Biparatopic construct according to claim 14, in which said one or more other groups, residues, moieties or binding units that provide the construct with increased half-life is chosen from the group consisting of serum proteins or fragments thereof, binding units that can bind to serum proteins, an Fc portion, and small proteins or peptides that can bind to serum proteins. 16. Biparatopic construct according to claim 15, in which said one or more other groups, residues, moieties or binding units that provides the construct with increased half-life are chosen from the group consisting of domain antibodies, single domain antibodies, V.sub.HHs, humanized V.sub.HHs, or camelized heavy chain variable domains that can bind to serum albumin, human serum albumin, a serum immunoglobulin, or IgG. 17. Nucleic acid or nucleotide sequence, that encodes a biparatopic construct according to claim 1. 18. Composition comprising at least a biparatopic construct according to claim 1. 19. Composition according to claim 18, which is a pharmaceutical composition that further comprises at least one pharmaceutically acceptable carrier, diluent or excipient and/or adjuvant, and that optionally comprises one or more further pharmaceutically active polypeptides and/or compounds. 20. A biparatopic construct comprising SEQ ID NO: 2342, SEQ ID NO: 2346, SEQ ID NO: 2347, or SEQ ID NO: 2348.

Details for Patent 9,969,805

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Grifols Therapeutics Llc	ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5	albumin (human)	For Injection	101138	10/21/1942		2027-11-27
Baxalta Us Inc.	BUMINATE, FLEXBUMIN	albumin (human)	Injection	101452	03/03/1954		2027-11-27
Csl Behring Ag	ALBURX	albumin (human)	Injection	102366	07/23/1976		2027-11-27
Grifols Biologicals Llc	ALBUTEIN	albumin (human)	Injection	102478	08/15/1978		2027-11-27
Instituto Grifols, S.a.	HUMAN ALBUMIN GRIFOLS	albumin (human)	Injection	103352	02/17/1995		2027-11-27
Instituto Grifols, S.a.	HUMAN ALBUMIN GRIFOLS	albumin (human)	Injection	103352	06/11/2003		2027-11-27
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2027-11-27